CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).
Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胃癌(GC)是一种治疗选择有限的恶性实体瘤,尤其是在晚期肿瘤阶段。
胃癌(GC)是一种治疗选择有限的恶性实体瘤,尤其是晚期肿瘤阶段。嵌合抗原受体(CAR)-T 疗法在治疗血液系统恶性肿瘤方面已取得成功;然而,由于复杂的肿瘤微环境(TME),其在实体瘤中的疗效仍不理想。GC 中的 TME 由多种信号分子和细胞成分组成,包括成纤维细胞、免疫细胞和基质蛋白;这些成分可支持肿瘤生长、侵袭和免疫逃逸。在 GC TME 中,细胞因子、趋化因子、生长因子及其受体之间的动态相互作用可促进慢性炎症和免疫抑制,从而促进肿瘤进展、转移和治疗耐药。本综述为理解 GC 中细胞-趋化因子相互作用网络及其功能影响提供了新的见解,强调了趋化因子在免疫治疗中的治疗意义。此外,还概述了当前相关研究领域,并讨论了靶向关键趋化因子信号通路的治疗策略进展。通过提供对 TME 重编程和免疫调节的重要见解,本研究旨在鼓励将趋化因子工程策略性地应用于 GC 的下一代 CAR-T 免疫治疗。
Gastric cancer (GC) is a malignant solid tumor with limited treatment options, particularly for advanced tumor stages. Chimeric antigen receptor (CAR)-T therapy has been successful in treating hematological malignancies; however, its efficacy in solid tumors remains suboptimal due to the complex tumor microenvironment (TME). The TME in GC comprises diverse signaling molecules and cellular components, including fibroblasts, immune cells and stromal proteins; these components can support tumor growth, invasion and immune evasion.
In the GC TME, the dynamic interactions between cytokines, chemokines, growth factors and their receptors can foster chronic inflammation and immunosuppression, thereby facilitating tumor progression, metastasis and therapeutic resistance. The present review provides novel insights into the understanding and functional impact of cell-chemokine interaction networks in GC, highlighting the therapeutic implications of chemokines in immunotherapy.
In addition, current related research areas are outlined and advances in therapeutic strategies targeting key chemokine signaling pathways are discussed. By providing critical insights into TME reprogramming and immunomodulation, the current study aims to encourage the strategic application of chemokine engineering in next-generation CAR-T immunotherapy for GC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。